This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
August 01, 2024: SEAM Group, a B2B business products and services company that provides safety, reliability, maintenance, and enterprise asset management services in the hospitality, food processing, and pharmaceutical industries, was acquired by ABB for an undisclosed amount.
Cooley’s M&A practice has been busy amid the typically slower summer wind down. Steaming through the third quarter, Cooley’s deal flow put us at the top of the Bloomberg, Mergermarket and Refinitiv Q3 M&A league tables. Transfer Traps: Considerations for Dual-Class Companies Contemplating M&A Transactions.
16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. PRINCETON, N.J., Nasdaq: ALIM) (“Alimera”).
Posted by Sally Wagner Partin, Sharon Flanagan, and Hannah M. Flanagan are Partners and Hannah M. Related research from the Program on Corporate Governance includes Are M&A Contract Clauses Value Relevant to Target and Bidder Shareholders? Brown is an Associate at Sidley Austin LLP.
25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., TARRYTOWN, N.Y., strengthening the company’s gene therapy and auditory programs.
16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. PRINCETON, N.J., Nasdaq: ALIM).
July 02, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. a Cayman Islands corporation and special purpose acquisition company (Nasdaq: DECA, “SPAC”), today announced the signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur up to $2.0 PALO ALTO, Calif.,
July 31, 2023 (GLOBE NEWSWIRE) -- Monster Beverage Corporation (NASDAQ: MNST) today announced that its subsidiary, Blast Asset Acquisition LLC, completed its acquisition of substantially all of the assets of Vital Pharmaceuticals, Inc. CORONA, Calif.,
Get the Insider Tips You Need to Secure Your Deal - Watch Here rn rn About the Guest(s): rn Patrick O'Connell is an experienced mergers and acquisitions (M&A) advisor with a profound depth of knowledge in buying and selling small businesses valued between one to $20 million. b' E200: Buying or Selling a Small Business?
10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. PRINCETON, N.J., Alimera”) (Nasdaq: ALIM).
AscellaHealth Announces Strategic Acquisition of CHAPPER healthcare: Expands Global Specialty Pharmaceutical Wholesale and Product Distribution Services
OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today that it has acquired: CHINO HILLS, Calif., 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc.
To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A). To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A).
Selechimica”), an Italian distributor in the pharmaceutical industry. ROTTERDAM, The Netherlands (10 June 2024) – IMCD N.V. IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Italy has signed an agreement to acquire 100% of the shares in Selechimica S.R.L.
a European distributor in the pharmaceutical and nutraceutical industry. ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to acquire 100% of the shares in Cobapharma, S.L.U,
March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. DEER PARK, Ill.,
22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., SAN DIEGO, Sept.
21, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of Aurlumyn ™ (iloprost IV), the only FDA approved treatment option for severe frostbite in the US, from CiVi Biopharma. Philadelphia, PA, Oct.
Healthcare Manufacturing Stands Out Two subsectors— Pharmaceutical Manufacturing and Medical Devices & Supplies —are drawing particularly deep interest. Yet, recent data tells a different story—one of strong and sustained interest in industrial businesses that are quietly powering some of the most active deal-making in the middle market.
September 2, 2024 – The software mergers and acquisitions (M&A) marketplace has been bustling with activity in the first half of 2024, reflecting the sector’s robust growth and strategic consolidations. billion acquisition of Ansys, a move aimed at bolstering its software capabilities and expanding its market footprint.
What’s on tap for 2018 M&A? No longer just “acquihires,” today’s innovation-driven acquisition is focused on talent retention. As an example, for California specific requirements, see our prior blog post Non-Competes for California Employees in M&A Deals: Don’t Fudge It. 280G Gross-Ups in Public Company Sales.
While Ivers-Lee will remain a separate legal entity, its operations will be integrated into Alvotech’s Technical Operations division, supporting Alvotech’s ambitious plans for growth.
Embracing Innovation in M&A Strategies As the M&A landscape evolves, the call for innovation grows louder. Enter freelance modeling—a dynamic concept that adapts M&A to the fast-paced, unpredictable realm of modern business. In the upcoming sections, we explore how freelance modeling reshapes M&A norms.
Mergers and acquisitions (M&A) constitute intricate and frequently risky transactions with significant implications for stakeholders. That’s why companies need to approach M&A deals with a strategic mindset that minimizes risk and maximizes value.
2019 was a banner year for billion-dollar life sciences M&A transactions. A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2
July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that its previously announced acquisition by the global pharmaceutical company, AstraZeneca, has closed.
Cergy, 9 October 2024 - SPIE, the independent European leader in multi-technical services in the areas of energy and communications, announces the acquisition of 88% of Spefinox, an expert player in industrial processes for the agri-food, cosmetics and pharmaceuticals sectors.
Posted by Sally Wagner Partin, Sharon Flanagan, and Hannah M. Flanagan are Partners and Hannah M. Related research from the Program on Corporate Governance includes Are M&A Contract Clauses Value Relevant to Target and Bidder Shareholders? Brown is an Associate at Sidley Austin LLP.
Philadelphia, PA, July 31, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of RSDL ® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. NYSE: EBS) for an up-front payment of approximately $75 million.
A key indicator is the increasing number of SaaS M&A transactions as companies seek to expand into new markets, consolidate current markets, provide end-to-end solutions, and take advantage of synergies. As a trusted partner in SaaS M&A, we are thrilled to have played a pivotal role in these significant deals.
SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. Nasdaq: CDT ) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation.
27, 2023 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of Scientific Support Services Ltd (“SSS” or the “Company”), a UK based provider of scientific instruments, supplies and services to customers in the petrochemical, environmental, pharmaceutical, clinical, and food and flavors sectors.
21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. CAMBRIDGE, Mass.,
22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has signed a Letter of Intent (“LOI”) with Seyltx Inc. VANCOUVER, British Columbia, Nov.
In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion, and Karina for $14 billion; AstraZeneca’s acquisition of Gracell Biotechnologies for up to $1.2
Olon, the leading chemical-pharmaceutical group in the production and development of active pharmaceutical ingredients (APIs) and part of the holding company P&R, continues its growth path and announces a new venture: it will acquire HuvePharma Italia Srl and its site in Garessio, (Cuneo, Italy) with a significant increase in its total production (..)
Galeras development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has closed on its agreement with Seyltx Inc.
Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in.
Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation
Corporate restructuring can be a game-changer for any organization, whether it’s a merger, acquisition, or any other strategic move. We, at Devensoft, help companies with their end-to-end M&A and have worked with several clients in the corporate sector to navigate this complex process.
04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. Harmony”) and its wholly owned subsidiary, Xylophone Acquisition Corp. Purchaser”), to purchase all outstanding shares of Zynerba common stock. The Zynerba Board of Directors unanimously recommends that Zynerba stockholders tender their shares pursuant to the Offer.
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content